查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1609114

多发性骨髓瘤药物市场：按类型、分销管道划分 - 全球预测 2025-2030 年

Multiple Myeloma Therapeutics Market by Type (Chemotherapy, Radiation, Stem Cell Transplant & Supportive Treatment), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies & Drug Stores) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年多发性骨髓瘤治疗市值为215.4亿美元，预计到2024年将达到229.5亿美元，复合年增长率为7.06%，到2030年将达到347.4亿美元，预计将达到1000万美元。

多发性骨髓瘤治疗市场的范围和定义包括开发和提供用于治疗多发性骨髓瘤的药物和治疗方法，多发性骨髓瘤是一种影响骨髓浆细胞的血癌。这些治疗药物的需求是由于全球发病率不断增加以及需要更有效治疗方案的患者数量不断增加。这些治疗方法包括传统化疗、免疫调节药物、蛋白酶体抑制剂和现代单株抗体。最终使用范围主要是进行这些治疗的医院、肿瘤中心和专科诊所。市场成长受到医疗保健支出增加、分子诊断技术进步以及专注于发现新治疗方法的研发活动活性化等关键因素的影响。新的商机主要在于个人化医疗、CAR T 细胞疗法的进步以及纳入新药物类别的扩展治疗指南。公司可以透过投资 FDA核准的临床试验和药物开发伙伴关係来利用这些机会。

主要市场统计
基准年[2023] 215.4亿美元
预测年份 [2024] 229.5亿美元
预测年份 [2030] 347.4亿美元
复合年增长率（%） 7.06%

然而，市场限制包括高昂的治疗成本、严格的法律规范以及与当前治疗方法相关的显着副作用，这可能会限制患者的依从性并导致治疗中断。这种疾病的复杂性质和抗治疗性提出了进一步的挑战。专注于开发毒性较小、更有效的下一代疗法的创新可能会推动市场成长。用于早期检测和治疗客製化的生物标记研究以及用于提高疗效的联合治疗具有巨大的业务成长潜力。鑑于市场竞争激烈，建议透过策略联盟和与研究机构联合研究来推动管道开发。总体而言，市场预计将大幅成长，但克服高成本和监管障碍的挑战对于维持业务扩张和改善患者治疗至关重要。

市场动态：揭示快速发展的多发性骨髓瘤药物市场的关键市场洞察

供需的动态交互作用正在改变多发性骨髓瘤药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 血癌患者增加
    • 世界老年人口的增加
    • 对多发性骨髓瘤先进治疗的需求不断增长
  • 市场限制因素
    • 多发性骨髓瘤治疗高成本
  • 市场机会
    • 多灶干细胞移植技术进展
    • 多发性骨髓瘤治疗的持续研究和开发活动
  • 市场挑战
    • 严格的政府法规

波特五力：驾驭多发性骨髓瘤药物市场的策略工具

波特的五力架构是了解多发性骨髓瘤治疗市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解多发性骨髓瘤药物市场的外部影响

外部宏观环境因素在塑造多发性骨髓瘤治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解多发性骨髓瘤治疗药物市场的竞争状况

多发性骨髓瘤治疗市场的详细市场占有率分析提供了对供应商绩效的全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵多发性骨髓瘤治疗市场供应商的绩效评估

FPNV定位矩阵是评估多发性骨髓瘤治疗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划多发性骨髓瘤药物市场的成功之路

对于希望加强在全球市场的影响力的公司来说，对多发性骨髓瘤治疗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 血癌病例增加
      • 世界各地的人口老化正在加剧。
      • 对多发性骨髓瘤先进治疗方法的需求不断增长
    • 抑制因素
      • 多发性骨髓瘤治疗费用高昂
    • 机会
      • 多细胞干细胞移植手术的技术进展
      • 正在进行的多发性骨髓瘤治疗研究和开发活动
    • 任务
      • 严格的政府规章制度
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 多发性骨髓瘤药物市场：依类型

  • 化疗
    • 组蛋白去乙酰化酶 (HDAC) 抑制剂
    • 免疫调节剂
    • 单株抗体
    • 蛋白酶体抑制剂
    • 常规化疗
  • 辐射
  • 干细胞移植和支持性治疗

第七章 多发性骨髓瘤药物市场：按通路

  • 医院药房
  • 网路药房
  • 零售药局/药局

第八章美洲多发性骨髓瘤药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区多发性骨髓瘤药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东及非洲多发性骨髓瘤药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Amgen, Inc.
  • Bristol-Myers Squibb Company
  • Celldex Therapeutics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genzyme Corporation
  • GlaxoSmithKline PLC
  • Innate Pharma SA
  • Johnson & Johnson Services, Inc.
  • Kesios Therapeutics Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-ED54C46E8354

The Multiple Myeloma Therapeutics Market was valued at USD 21.54 billion in 2023, expected to reach USD 22.95 billion in 2024, and is projected to grow at a CAGR of 7.06%, to USD 34.74 billion by 2030.

The scope and definition of the Multiple Myeloma Therapeutics market involve the development and delivery of drugs and therapies designed to treat multiple myeloma, a type of blood cancer that affects plasma cells in bone marrow. The necessity of these therapeutics stems from the increasing incidence of the disease worldwide and the growing patient population requiring more effective treatment options. Application of these therapeutics includes the use of traditional chemotherapies, immunomodulatory drugs, proteasome inhibitors, and the latest monoclonal antibodies to manage the disease. End-use scope primarily covers hospitals, oncology centers, and specialty clinics where these treatments are administered. Market growth is influenced by key factors such as rising healthcare expenditure, advancements in molecular diagnostics, and the escalation of R&D activities focused on discovering novel therapies. Emerging opportunities primarily lie in the advancement of personalized medicine, CAR T-cell therapy, and the expansion of treatment guidelines incorporating newer drug classes. Companies can capitalize on these opportunities by investing in clinical trials for FDA approvals and partnerships for drug development.

KEY MARKET STATISTICS
Base Year [2023] USD 21.54 billion
Estimated Year [2024] USD 22.95 billion
Forecast Year [2030] USD 34.74 billion
CAGR (%) 7.06%

However, market limitations include high treatment costs, stringent regulatory frameworks, and significant side effects associated with current therapies, which can restrict patient adherence and lead to treatment drop-offs. The complex nature of the disease and treatment resistance poses additional challenges. Innovations focusing on the development of less toxic and more effective next-generation therapies could spur market growth. Research into biomarkers for early detection and treatment customization, as well as combination therapies to improve efficacy, presents significant business growth potential. Given the competitive nature of the market, strategic alliances and collaborations with research institutes to drive pipeline development are recommended. Overall, while the market holds substantial growth prospects, overcoming the challenges of high costs and regulatory hurdles will be critical to sustaining business expansion and enhancing patient outcomes.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Multiple Myeloma Therapeutics Market

The Multiple Myeloma Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rise in the cases of blood cancers
    • Increasing geriatric population across the globe
    • Growing need for advanced therapeutics for multiple myeloma
  • Market Restraints
    • High cost associated with the treatment of multiple myeloma
  • Market Opportunities
    • Technological advancement in the multiple stem cell transplant procedures
    • Ongoing research and development activities in multiple myeloma therapeutics
  • Market Challenges
    • Strict rules and regulations of the government

Porter's Five Forces: A Strategic Tool for Navigating the Multiple Myeloma Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Multiple Myeloma Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Multiple Myeloma Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Multiple Myeloma Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Multiple Myeloma Therapeutics Market

A detailed market share analysis in the Multiple Myeloma Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Multiple Myeloma Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Multiple Myeloma Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Multiple Myeloma Therapeutics Market

A strategic analysis of the Multiple Myeloma Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Multiple Myeloma Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen, Inc., Bristol-Myers Squibb Company, Celldex Therapeutics, Inc., F. Hoffmann-La Roche Ltd., Genzyme Corporation, GlaxoSmithKline PLC, Innate Pharma SA, Johnson & Johnson Services, Inc., Kesios Therapeutics Ltd., Merck & Co., Inc., Novartis AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Multiple Myeloma Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Chemotherapy, Radiation, and Stem Cell Transplant & Supportive Treatment. The Chemotherapy is further studied across Histone Deacetylase (HDAC) Inhibitors, Immunomodulating Agents, Monoclonal Antibodies, Proteasome Inhibitors, and Traditional Chemotherapy.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies & Drug Stores.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in the cases of blood cancers
      • 5.1.1.2. Increasing geriatric population across the globe
      • 5.1.1.3. Growing need for advanced therapeutics for multiple myeloma
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with the treatment of multiple myeloma
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancement in the multiple stem cell transplant procedures
      • 5.1.3.2. Ongoing research and development activities in multiple myeloma therapeutics
    • 5.1.4. Challenges
      • 5.1.4.1. Strict rules and regulations of the government
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Multiple Myeloma Therapeutics Market, by Type

  • 6.1. Introduction
  • 6.2. Chemotherapy
    • 6.2.1. Histone Deacetylase (HDAC) Inhibitors
    • 6.2.2. Immunomodulating Agents
    • 6.2.3. Monoclonal Antibodies
    • 6.2.4. Proteasome Inhibitors
    • 6.2.5. Traditional Chemotherapy
  • 6.3. Radiation
  • 6.4. Stem Cell Transplant & Supportive Treatment

7. Multiple Myeloma Therapeutics Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Hospital Pharmacies
  • 7.3. Online Pharmacies
  • 7.4. Retail Pharmacies & Drug Stores

8. Americas Multiple Myeloma Therapeutics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Multiple Myeloma Therapeutics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Multiple Myeloma Therapeutics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen, Inc.
  • 3. Bristol-Myers Squibb Company
  • 4. Celldex Therapeutics, Inc.
  • 5. F. Hoffmann-La Roche Ltd.
  • 6. Genzyme Corporation
  • 7. GlaxoSmithKline PLC
  • 8. Innate Pharma SA
  • 9. Johnson & Johnson Services, Inc.
  • 10. Kesios Therapeutics Ltd.
  • 11. Merck & Co., Inc.
  • 12. Novartis AG
  • 13. Sanofi S.A.
  • 14. Takeda Pharmaceutical Company Limited
  • 15. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. MULTIPLE MYELOMA THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. MULTIPLE MYELOMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. MULTIPLE MYELOMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MULTIPLE MYELOMA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MULTIPLE MYELOMA THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HISTONE DEACETYLASE (HDAC) INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TRADITIONAL CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY RADIATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY STEM CELL TRANSPLANT & SUPPORTIVE TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES & DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. MULTIPLE MYELOMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. MULTIPLE MYELOMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023